Literature DB >> 25917493

Characterising temporal trends in asymptomatic Plasmodium infections and transporter polymorphisms during transition from high to low transmission in Zanzibar, 2005-2013.

Ulrika Morris1, Weiping Xu2, Mwinyi I Msellem3, Alanna Schwartz4, Ali Abass3, Delér Shakely5, Jackie Cook6, Achuyt Bhattarai7, Max Petzold8, Bryan Greenhouse4, Abdullah S Ali3, Anders Björkman2, Gabrielle Fröberg9, Andreas Mårtensson10.   

Abstract

BACKGROUND: Improved understanding of the asymptomatic malaria parasite reservoir is a prerequisite to pursue malaria elimination efforts. We therefore characterised temporal trends and transporter polymorphisms in asymptomatic Plasmodium infections during the transition from high to low transmission in Zanzibar.
METHODS: Healthy individuals participating in cross-sectional surveys conducted 2005-2013 were screened for asymptomatic malaria by PCR. Complexity/diversity of infection and transporter polymorphisms were assessed in Plasmodium falciparum positive samples. Symptomatic samples were included for comparison of polymorphisms in 2013.
RESULTS: PCR-determined parasite prevalence declined from 21.1% (CI95% 17.4-24.9) to 2.3% (CI95% 1.7-2.9) from 2005 to 2013. P. falciparum remained the predominant species; prevalence was highest in children and young adults aged 5-25 years. Parasite densities and complexity of infection, but not population genetic diversity of P. falciparum, decreased from 2005-2009. pfcrt 76T (99.2-64.7%, p < 0.001) and pfmdr1 86Y frequencies (89.4-66.7%, p = 0.03) decreased over time. Pfmdr1 (a.a.86,184,1246) YYY and YYD haplotypes were more frequent in asymptomatic than symptomatic infections in 2013 (p < 0.001).
CONCLUSIONS: There is a declining, albeit persistent, reservoir of parasites present at low-densities in asymptomatic individuals in Zanzibar. This study revealed important characteristics of the remaining parasite population, including intriguing temporal trends in molecular markers associated with antimalarial resistance, which need to be further investigated.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Antimalarial drug resistance markers; Asymptomatic; Low transmission; Molecular surveillance; Plasmodium

Mesh:

Substances:

Year:  2015        PMID: 25917493     DOI: 10.1016/j.meegid.2015.04.018

Source DB:  PubMed          Journal:  Infect Genet Evol        ISSN: 1567-1348            Impact factor:   3.342


  11 in total

1.  Dynamics of Plasmodium falciparum genetic diversity among asymptomatic and symptomatic children in three epidemiological areas in Cote d'Ivoire.

Authors:  Akpa Paterne Gnagne; Abibatou Konate; Akoua Valérie Bedia-Tanoh; Mireille Amiah-Droh; Hervé Ignace Eby Menan; Assanvo Simon-Pierre N'Guetta; William Yavo
Journal:  Pathog Glob Health       Date:  2019-05-30       Impact factor: 2.894

2.  Field deployment of loop-mediated isothermal amplification for centralized mass-screening of asymptomatic malaria in Zanzibar: a pre-elimination setting.

Authors:  Ulrika Morris; Mwinyi Khamis; Berit Aydin-Schmidt; Ali K Abass; Mwinyi I Msellem; Majda H Nassor; Iveth J González; Andreas Mårtensson; Abdullah S Ali; Anders Björkman; Jackie Cook
Journal:  Malar J       Date:  2015-05-17       Impact factor: 2.979

3.  The return of chloroquine-susceptible Plasmodium falciparum malaria in Zambia.

Authors:  Sydney Mwanza; Sudhaunshu Joshi; Michael Nambozi; Justin Chileshe; Phidelis Malunga; Jean-Bertin Bukasa Kabuya; Sebastian Hachizovu; Christine Manyando; Modest Mulenga; Miriam Laufer
Journal:  Malar J       Date:  2016-12-05       Impact factor: 2.979

4.  Field Evaluation of a High Throughput Loop Mediated Isothermal Amplification Test for the Detection of Asymptomatic Plasmodium Infections in Zanzibar.

Authors:  Berit Aydin-Schmidt; Ulrika Morris; Xavier C Ding; Irina Jovel; Mwinyi I Msellem; Daniel Bergman; Atiqul Islam; Abdullah S Ali; Spencer Polley; Iveth J Gonzalez; Andreas Mårtensson; Anders Björkman
Journal:  PLoS One       Date:  2017-01-17       Impact factor: 3.240

5.  Increased Sensitivity of Plasmodium falciparum to Artesunate/Amodiaquine Despite 14 Years as First-Line Malaria Treatment, Zanzibar.

Authors:  Mwinyi Msellem; Ulrika Morris; Aungpaing Soe; Faiza B Abbas; Abdul-Wahid Ali; Rory Barnes; Paolo Frumento; Abdullah S Ali; Andreas Mårtensson; Anders Björkman
Journal:  Emerg Infect Dis       Date:  2020-08       Impact factor: 6.883

6.  Emerging implications of policies on malaria treatment: genetic changes in the Pfmdr-1 gene affecting susceptibility to artemether-lumefantrine and artesunate-amodiaquine in Africa.

Authors:  Lucy C Okell; Lisa Malene Reiter; Lene Sandø Ebbe; Vito Baraka; Donal Bisanzio; Oliver J Watson; Adam Bennett; Robert Verity; Peter Gething; Cally Roper; Michael Alifrangis
Journal:  BMJ Glob Health       Date:  2018-10-19

7.  A cluster randomised controlled trial of two rounds of mass drug administration in Zanzibar, a malaria pre-elimination setting-high coverage and safety, but no significant impact on transmission.

Authors:  Ulrika Morris; Mwinyi I Msellem; Humphrey Mkali; Atiqul Islam; Berit Aydin-Schmidt; Irina Jovel; Shija Joseph Shija; Mwinyi Khamis; Safia Mohammed Ali; Lamija Hodzic; Ellinor Magnusson; Eugenie Poirot; Adam Bennett; Michael C Sachs; Joel Tarning; Andreas Mårtensson; Abdullah S Ali; Anders Björkman
Journal:  BMC Med       Date:  2018-12-10       Impact factor: 8.775

8.  Efficacy and safety of artemether-lumefantrine for the treatment of uncomplicated malaria and prevalence of Pfk13 and Pfmdr1 polymorphisms after a decade of using artemisinin-based combination therapy in mainland Tanzania.

Authors:  Deus S Ishengoma; Celine I Mandara; Filbert Francis; Eldin Talundzic; Naomi W Lucchi; Billy Ngasala; Abdunoor M Kabanywanyi; Muhidin K Mahende; Erasmus Kamugisha; Reginald A Kavishe; Florida Muro; Ally Mohamed; Renata Mandike; Sigsbert Mkude; Frank Chacky; Lynn Paxton; George Greer; Chonge A Kitojo; Ritha Njau; Troy Martin; Meera Venkatesan; Marian Warsame; Eric S Halsey; Venkatachalam Udhayakumar
Journal:  Malar J       Date:  2019-03-21       Impact factor: 2.979

9.  The temporal dynamics and infectiousness of subpatent Plasmodium falciparum infections in relation to parasite density.

Authors:  Hannah C Slater; Amanda Ross; Ingrid Felger; Natalie E Hofmann; Leanne Robinson; Jackie Cook; Bronner P Gonçalves; Anders Björkman; Andre Lin Ouedraogo; Ulrika Morris; Mwinyi Msellem; Cristian Koepfli; Ivo Mueller; Fitsum Tadesse; Endalamaw Gadisa; Smita Das; Gonzalo Domingo; Melissa Kapulu; Janet Midega; Seth Owusu-Agyei; Cécile Nabet; Renaud Piarroux; Ogobara Doumbo; Safiatou Niare Doumbo; Kwadwo Koram; Naomi Lucchi; Venkatachalam Udhayakumar; Jacklin Mosha; Alfred Tiono; Daniel Chandramohan; Roly Gosling; Felista Mwingira; Robert Sauerwein; Richard Paul; Eleanor M Riley; Nicholas J White; Francois Nosten; Mallika Imwong; Teun Bousema; Chris Drakeley; Lucy C Okell
Journal:  Nat Commun       Date:  2019-03-29       Impact factor: 14.919

10.  Surveillance of genetic markers associated with Plasmodium falciparum resistance to artemisinin-based combination therapy in Pakistan, 2018-2019.

Authors:  Abdul Qader Khan; Leyre Pernaute-Lau; Aamer Ali Khattak; Sanna Luijcx; Berit Aydin-Schmidt; Mubashir Hussain; Taj Ali Khan; Farees Uddin Mufti; Ulrika Morris
Journal:  Malar J       Date:  2020-06-08       Impact factor: 2.979

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.